SHP2's gain‐of‐function in Werner syndrome causes childhood disease onset likely resulting from negative genetic interaction
暂无分享,去创建一个
R. Carrozzo | B. Dallapiccola | M. Tartaglia | C. Leoni | G. Zampino | M. Motta | C. Mancini | S. Martinelli | C. Mammı̀ | A. Ciolfi | F. C. Radio | M. Niceta | P. Pichierri | M. Priolo | V. Muto | L. Pannone | L. Pintomalli | Valentina Palermo | F. Aiello | Giuseppe Rajola | C. Mammi'
[1] Jenny J. Li,et al. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence , 2021, Scientific Reports.
[2] R. Hennekam. Pathophysiology of premature aging characteristics in Mendelian progeroid disorders. , 2020, European journal of medical genetics.
[3] C. Vigouroux,et al. Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants , 2020, Clinical genetics.
[4] E. Shagimardanova,et al. PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein , 2020, Biochemistry (Moscow).
[5] M. Rooman,et al. Digenic inheritance of human primary microcephaly delineates centrosomal and non‐centrosomal pathways , 2019, Human mutation.
[6] Ben Lehner,et al. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy , 2019, Nature Genetics.
[7] A. Rehman,et al. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. , 2019, Current pharmaceutical design.
[8] A. Asaithamby,et al. Werner Syndrome Protein and DNA Replication , 2018, International journal of molecular sciences.
[9] J. Cruysberg,et al. Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients , 2018, European Journal of Pediatrics.
[10] J. Li,et al. Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response. , 2017, Cancer research.
[11] Monia Magliozzi,et al. Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome , 2017, Human mutation.
[12] Donna M. Muzny,et al. Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation , 2017, The New England journal of medicine.
[13] M. Poot,et al. WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects , 2017, Human mutation.
[14] B. Neel,et al. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies , 2016, Proceedings of the National Academy of Sciences.
[15] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[16] F. d’Adda di Fagagna,et al. Stable Cellular Senescence Is Associated with Persistent DDR Activation , 2014, PloS one.
[17] V. Bohr,et al. Human RecQ helicases in DNA repair, recombination, and replication. , 2014, Annual review of biochemistry.
[18] C. Myers,et al. Genetic interaction networks: toward an understanding of heritability. , 2013, Annual review of genomics and human genetics.
[19] B. Donadille,et al. Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome , 2013, Orphanet Journal of Rare Diseases.
[20] T. Miki,et al. Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey , 2013, Geriatrics & gerontology international.
[21] R. Monnat,et al. Spectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review , 2013, PloS one.
[22] Y. Ishikawa,et al. Werner syndrome: a changing pattern of clinical manifestations in Japan (1917~2008). , 2013, Bioscience trends.
[23] M. Bignami,et al. The Werner syndrome protein: linking the replication checkpoint response to genome stability , 2011, Aging.
[24] B. Gelb,et al. Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.
[25] M. Bignami,et al. ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery , 2010, The EMBO journal.
[26] V. Bohr,et al. Roles of Werner syndrome protein in protection of genome integrity. , 2010, DNA repair.
[27] T. Hakoshima,et al. Structural basis for DNA strand separation by the unconventional winged-helix domain of RecQ helicase WRN. , 2010, Structure.
[28] J. Chambard,et al. ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence , 2010, The FEBS journal.
[29] S. Carr,et al. A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint , 2010, PLoS biology.
[30] Lye Mun Tho,et al. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.
[31] T. Matozaki,et al. Protein tyrosine phosphatase SHP‐2: A proto‐oncogene product that promotes Ras activation , 2009, Cancer science.
[32] K. Kawakami,et al. Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells , 2009, Disease Models & Mechanisms.
[33] B. Neel,et al. The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.
[34] Markus Schuelke,et al. The spectrum of WRN mutations in Werner syndrome patients , 2006, Human mutation.
[35] R. Foà,et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.
[36] X. Xi,et al. Solution structure of a multifunctional DNA- and protein-binding motif of human Werner syndrome protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] R. Verdun,et al. Defective Telomere Lagging Strand Synthesis in Cells Lacking WRN Helicase Activity , 2004, Science.
[38] M. Loh,et al. SHP-2 and myeloid malignancies. , 2004, Current opinion in hematology.
[39] F. Rosselli,et al. Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle , 2003, Oncogene.
[40] M. Emond,et al. Homologous Recombination Resolution Defect in Werner Syndrome , 2002, Molecular and Cellular Biology.
[41] M. Poot,et al. Werner syndrome diploid fibroblasts are sensitive to 4‐nitroquinoline‐N‐oxide and 8‐methoxypsoralen: implications for the disease phenotype , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] J. Oshima,et al. Werner Syndrome , 2020, Constitutional Oncogenetics.
[43] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[44] P. Mosesso,et al. Werner's syndrome protein is required for correct recovery after replication arrest and DNA damage induced in S-phase of cell cycle. , 2001, Molecular biology of the cell.
[45] I. Saira Mian,et al. The premature ageing syndrome protein, WRN, is a 3′→5′ exonuclease , 1998, Nature Genetics.
[46] S. Shoelson,et al. Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.
[47] M. Gray,et al. The Werner syndrome protein is a DNA helicase , 1997, Nature Genetics.
[48] G. Schellenberg,et al. Positional Cloning of the Werner's Syndrome Gene , 1996, Science.